Literature DB >> 18422389

TNF-alpha inhibitors and leukaemia: international pharmacovigilance reports.

Ronald H B Meyboom, Kristina Star, Jenny Bate, Ruth Savage, I Ralph Edwards.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18422389     DOI： 10.2165/00002018-200831050-00013

Source DB:  PubMed          Journal:  Drug Saf        ISSN： 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  11 in total

1.  Acute leukemia after infliximab therapy.

Authors:  Guillermo Alcaín; Raúl J Andrade; María P Queipo de Llano; María J Moreno; Miren García-Cortés; Eduardo Franquelo
Journal:  Am J Gastroenterol       Date:  2003-11       Impact factor: 10.864

2.  Chronic myeloid leukaemia and tuberculosis in a patient with rheumatoid arthritis treated with infliximab.

Authors:  F Broussais; M Kawashima; H Marotte; P Miossec
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

3.  Acute myelogenous leukemia in a patient receiving etanercept for psoriasis.

Authors:  Claude Bachmeyer; Brigitte Thiolière; Kiarash Khosrotehrani; Elie Cattan
Journal:  J Am Acad Dermatol       Date:  2007-01       Impact factor: 11.527

4.  The role of the WHO programme on International Drug Monitoring in coordinating worldwide drug safety efforts.

Authors:  S Olsson
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

5.  Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.

Authors:  Eva Baecklund; Anastasia Iliadou; Johan Askling; Anders Ekbom; Carin Backlin; Fredrik Granath; Anca Irinel Catrina; Richard Rosenquist; Nils Feltelius; Christer Sundström; Lars Klareskog
Journal:  Arthritis Rheum       Date:  2006-03

6.  Risk of malignancy among patients with rheumatic conditions.

Authors:  E Thomas; D H Brewster; R J Black; G J Macfarlane
Journal:  Int J Cancer       Date:  2000-11-01       Impact factor: 7.396

7.  Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.

Authors:  J Askling; C M Fored; E Baecklund; L Brandt; C Backlin; A Ekbom; C Sundström; L Bertilsson; L Cöster; P Geborek; L T Jacobsson; S Lindblad; J Lysholm; S Rantapää-Dahlqvist; T Saxne; L Klareskog; N Feltelius
Journal:  Ann Rheum Dis       Date:  2005-04-20       Impact factor: 19.103

Review 8.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Authors:  Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori
Journal:  JAMA       Date:  2006-05-17       Impact factor: 56.272

9.  Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study.

Authors:  David P Steensma; Ruben A Mesa; Chin-Yang Li; Leigh Gray; Ayalew Tefferi
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

Review 10.  Under-reporting of adverse drug reactions : a systematic review.

Authors:  Lorna Hazell; Saad A W Shakir
Journal:  Drug Saf       Date:  2006       Impact factor: 5.228
View more
  7 in total

Review 1.  Pharmacovigilance of biopharmaceuticals: challenges remain.

Authors:  Thijs J Giezen; Aukje K Mantel-Teeuwisse; Hubert G M Leufkens
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 2.  Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.

Authors:  Archana Jain; Jasvinder A Singh
Journal:  Immunotherapy       Date:  2013-03       Impact factor: 4.196

3.  Safety profile of biological medicines as compared with non-biologicals: an analysis of the italian spontaneous reporting system database.

Authors:  Paola M Cutroneo; Valentina Isgrò; Alessandra Russo; Valentina Ientile; Laura Sottosanti; Giuseppe Pimpinella; Anita Conforti; Ugo Moretti; Achille P Caputi; Gianluca Trifirò
Journal:  Drug Saf       Date:  2014-11       Impact factor: 5.606

4.  Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.

Authors:  Thijs J Giezen; Aukje K Mantel-Teeuwisse; Ronald H B Meyboom; Sabine M J M Straus; Hubert G M Leufkens; Toine C G Egberts
Journal:  Drug Saf       Date:  2010-10-01       Impact factor: 5.606

5.  Sources of information on lymphoma associated with anti-tumour necrosis factor agents: comparison of published case reports and cases reported to the French pharmacovigilance system.

Authors:  Hélène Théophile; Thierry Schaeverbeke; Ghada Miremont-Salamé; Abdelilah Abouelfath; Valentine Kahn; Françoise Haramburu; Bernard Bégaud
Journal:  Drug Saf       Date:  2011-07-01       Impact factor: 5.606

6.  Leukaemic transformation in patients with haematological disease receiving tumour necrosis factor inhibitors.

Authors:  Francisca Ferrer-Marín; Maria Luz Amigo; Vicente Vicente
Journal:  Clin Drug Investig       Date:  2012-06-01       Impact factor: 2.859

7.  Challenges in the management of juvenile idiopathic arthritis with etanercept.

Authors:  Clare E Pain; Liza J McCann
Journal:  Biologics       Date:  2009-07-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.